SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03363555|
Recruitment Status : Active, not recruiting
First Posted : December 6, 2017
Last Update Posted : June 18, 2020
|Condition or disease||Intervention/treatment||Phase|
|Extranodal NK/T-cell Lymphoma, Nasal Type||Drug: SHR-1210||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||97 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-Label, Single Arm, Multi-Center, Phase 2 Study of PD-1 Antibody SHR-1210 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma|
|Actual Study Start Date :||May 29, 2018|
|Actual Primary Completion Date :||June 30, 2019|
|Estimated Study Completion Date :||June 2021|
SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes.
A humanized monoclonal immunoglobulin.
- objective response rate [ Time Frame: from first patient first visit to 6 month after last patient first visit ]rate of subjects achieved complete response plus partial response in all evaluable subjects
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03363555
|First Affiliated Hospital of Zhengzhou University|
|Zhengzhou, Henan, China|